ETF盘中资讯|续创阶段新低，港股通创新药ETF（520880）溢价逆向走高，千万资金逢跌揽筹！机构：2026年战略性布局创新药

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) has experienced a continuous decline for four days, reaching a new low since July 10, indicating a strong buying interest despite the downturn [1][2]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a price drop of 0.80%, currently priced at 0.499, with a trading volume of 124,339 shares [1]. - The ETF has been in a downward trend since September, with the current adjustment lasting over three months, leading to the ETF trading below its issuance price [2]. Group 2: Investment Strategy - Analysts suggest that 2026 will be a strategic year for investing in innovative drugs, as the current market conditions may present a favorable entry point for investors [2]. - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three key advantages: it exclusively includes innovative drug companies, has a high concentration of leading firms (over 72% in the top ten), and offers better risk control by reducing the weight of less liquid stocks [2][3]. Group 3: Composition and Risk Management - The top ten holdings of the ETF account for 72.57% of its total weight, showcasing a significant concentration in leading innovative drug companies [3]. - The ETF is designed to mitigate risks associated with less liquid stocks by enforcing a forced reduction in their weight, thus controlling tail risks effectively [2][3].